| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (NCT05142696) | Novartis Pharmaceuticals | 2022-07-13 |
| Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer (NCT05309629) | Qilu Pharmaceutical Co., Ltd. | 2022-04-18 |
| Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer (NCT04397003) | Washington University School of Medicine | 2022-03-30 |
| Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (NCT05280470) | Daiichi Sankyo | 2022-03-09 |
| Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC (NCT05092412) | You Lu | 2022-03-02 |
| Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy (NCT05796089) | Trans Tasman Radiation Oncology Group | 2022-01-01 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (NCT04774380) | AstraZeneca | 2021-11-11 |
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (NCT05002868) | Rhizen Pharmaceuticals SA | 2021-10-05 |
| To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (NCT04894591) | Jazz Pharmaceuticals | 2021-06-28 |
| Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer (NCT04933175) | Liu Zhenhua | 2021-06-01 |
| Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients (NCT04902885) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-05-25 |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (NCT04699838) | Muhammad Furqan | 2021-04-20 |
| a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer (NCT04790539) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-04-01 |
| Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer (NCT05761977) | Hellenic Cooperative Oncology Group | 2021-03-31 |
| A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (NCT04702880) | Bristol-Myers Squibb | 2021-03-17 |
| Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (NCT04487756) | Instituto Oncológico Dr Rosell | 2021-03-17 |
| Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC (NCT05001412) | Zhou Chengzhi | 2021-01-27 |
| Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer (NCT04947774) | Chinese Academy of Medical Sciences | 2020-11-01 |
| Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (NCT04373369) | Washington University School of Medicine | 2020-10-07 |
| SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC (NCT04562337) | Shandong Cancer Hospital and Institute | 2020-10-01 |
| Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC (NCT04663438) | Peking Union Medical College Hospital | 2020-06-30 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (NCT04101357) | BioNTech SE | 2020-06-19 |
| A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer (NCT04404543) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2020-06-01 |
| A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (NCT04636762) | Second Xiangya Hospital of Central South University | 2020-06-01 |
| Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer (NCT04346914) | Lee's Pharmaceutical Limited | 2020-03-08 |
| Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer (NCT04213937) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-01-31 |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients (NCT04254471) | Haihe Biopharma Co., Ltd. | 2019-11-14 |
| A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC (NCT04063163) | Shanghai Henlius Biotech | 2019-09-12 |
| Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy (NCT04056949) | Junling Li | 2019-08-05 |
| Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (NCT03911219) | iOMEDICO AG | 2019-07-10 |
| Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer (NCT03913455) | Shadia Jalal, MD | 2019-06-06 |
| PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (NCT03971214) | Chinese Academy of Medical Sciences | 2019-06-01 |
| Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer (NCT03841136) | Fudan University | 2019-04-01 |
| Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer (NCT05055947) | Hunan Province Tumor Hospital | 2019-04-01 |
| Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer (NCT05055999) | Hunan Province Tumor Hospital | 2019-04-01 |
| Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer (NCT04675697) | Xiangya Hospital of Central South University | 2019-01-24 |
| Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (NCT03711305) | Jiangsu HengRui Medicine Co., Ltd. | 2018-12-30 |
| Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer (NCT03781869) | Third Military Medical University | 2018-12-01 |
| A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer (NCT03516084) | Zai Lab (Shanghai) Co., Ltd. | 2018-08-20 |
| SGI-110 Plus Durvalumab/Tremelimumab in SCLC (NCT03085849) | Catherine Shu | 2017-12-15 |
| Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy (NCT03135977) | Sichuan Cancer Hospital and Research Institute | 2017-03-01 |
| Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (NCT03043599) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-13 |
| Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic (NCT02972320) | Yunpeng Liu | 2016-06-01 |
| Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer (NCT02772107) | Chinese PLA General Hospital | 2015-12-01 |
| Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer (NCT02194049) | University of California, Davis | 2014-07-01 |
| Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy (NCT02011087) | Wake Forest University Health Sciences | 2014-02-01 |
| Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients (NCT01999881) | University of Wisconsin, Madison | 2013-12-01 |
| Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer (NCT01987232) | Amgen | 2013-11-05 |
| Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers (NCT01935336) | University of Colorado, Denver | 2013-09-24 |
| Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer (NCT01803269) | University of Chicago | 2013-01-16 |
| Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer (NCT01563601) | Cephalon | 2012-08-01 |
| Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) (NCT01555710) | Alaunos Therapeutics | 2012-05-01 |
| The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (NCT01331525) | University Hospital Southampton NHS Foundation Trust | 2011-06-01 |
| Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer (NCT02323737) | Chinese Academy of Medical Sciences | 2010-07-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer (NCT01076504) | SCRI Development Innovations, LLC | 2009-12-01 |
| S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer (NCT00828139) | National Cancer Institute (NCI) | 2009-05-01 |
| QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (NCT00791154) | NantCell, Inc. | 2008-12-02 |
| R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer (NCT00773955) | National Cancer Institute (NCI) | 2008-11-01 |
| Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC (NCT00616109) | University of Michigan Rogel Cancer Center | 2007-09-01 |
| R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer (NCT00544596) | National Cancer Institute (NCI) | 2007-09-01 |
| Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer (NCT00470054) | National Cancer Institute (NCI) | 2007-04-01 |
| Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer (NCT00079040) | National Cancer Institute (NCI) | 2006-01-01 |
| Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer (NCT00182689) | National Cancer Institute (NCI) | 2005-07-01 |
| 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer (NCT00098956) | National Cancer Institute (NCI) | 2005-01-01 |
| Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer (NCT00118235) | National Cancer Institute (NCI) | 2004-12-01 |
| Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer (NCT00057837) | Eastern Cooperative Oncology Group | 2004-07-14 |
| Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy (NCT00084487) | National Cancer Institute (NCI) | 2004-04-01 |
| Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer (NCT00042978) | National Cancer Institute (NCI) | 2003-04-01 |
| CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer (NCT00028028) | National Cancer Institute (NCI) | 2002-02-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer (NCT00017251) | National Cancer Institute (NCI) | 2001-04-01 |
| FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer (NCT00020202) | National Cancer Institute (NCI) | 2000-06-01 |
| Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer (NCT00019006) | National Cancer Institute (NCI) | 1995-03-01 |
| Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer (NCT07535359) | Daiichi Sankyo | |